Skip to main content
Help us understand how you use our websites. Take part in our 30 minute study now.
Download PDF

Hajdu-Cheney syndrome: a review

Orphanet Journal of Rare Diseases volume 9, Article number: 200 (2014) Cite this article

Abstract

Hajdu Cheney Syndrome (HCS), Orpha 955, is a rare disease characterized by acroosteolysis, severe osteoporosis, short stature, specific craniofacial features, wormian bones, neurological symptoms, cardiovascular defects and polycystic kidneys. HCS is rare and is inherited as autosomal dominant although many sporadic cases have been reported. HCS is associated with mutations in exon 34 of NOTCH2 upstream the PEST domain that lead to the creation of a truncated and stable NOTCH2 protein with enhanced NOTCH2 signaling activity. Although the number of cases with NOTCH2 mutations reported are limited, it would seem that the diagnosis of HCS can be established by sequence analysis of exon 34 of NOTCH2. Notch receptors are single-pass transmembrane proteins that determine cell fate, and play a critical role in skeletal development and homeostasis. Dysregulation of Notch signaling is associated with skeletal developmental disorders. There is limited information about the mechanisms of the bone loss and acroosteolysis in HCS making decisions regarding therapeutic intervention difficult. Bone antiresorptive and anabolic agents have been tried to treat the osteoporosis, but their benefit has not been established. In conclusion, Notch regulates skeletal development and bone remodeling, and gain-of-function mutations of NOTCH2 are associated with HCS.

Review

Disease name/synonyms

Hajdu-Cheney syndrome; Acroosteolysis dominant type; Serpentine fibula polycystic kidney syndrome; Orpha number: 955

Definition

Hajdu-Cheney syndrome (HCS) is a rare inherited connective tissue disease characterized by acroosteolysis of hands and feet, developmental defects of bones, teeth and joints causing distinctive craniofacial and skull changes, and also manifested by severe osteoporosis and short stature. The disease was first described by Hajdu in 1948 in a 37 year old accountant who died 12 years later of severe neurological complications, and the syndrome was reported further by Cheney in 1965 (Table 1) [1],[2].

Table 1 Hajdu-Cheney syndrome clinical features
Full size table

Epidemiology

HCS is a rare disease; less than 100 cases have been reported, but its exact prevalence is unknown.

Clinical description

Hajdu-Cheney syndrome (HCS) is a rare disease with autosomal genetic inheritance, although the disease can also have sporadic presentations. It is characterized by acroosteolysis of distal phalanges, severe osteoporosis with fractures, craniofacial and dental abnormalities and short stature [1]-[7]. Patients with HCS exhibit prominent skeletal features including facial dysmorphisms, craniofacial defects, such as micrognathia, mid-face flattening and dental abnormalities. There is high clinical variability and a phenotypical evolution of the clinical manifestations. Some signs of the disease, such as synophrys, hypotelorism and epicanthal folds present as early as in the first two years of life and others become more evident in young children and adolescents, so that facial features become coarser over time [7]. Eventually, adult patients develop classic features of craniofacial dysmorphism characterized by bathrocephaly with prominent occiput, mild hypertelorism with telecanthus, downslanted eyes with synophrys, low-set ears, long philtrum, micrognathia with highly arched palate or cleft palate, and short neck. Acroosteolysis is frequently observed and can present with symptoms of inflammation, including pain and swelling. Patients have short and broad digits. Generalized and local joint hypermobility are reported frequently. Spinal abnormalities include compression fractures, deformities, kyphosis, scoliosis, platybasia and basilar invagination. Long bone deformities such as serpentine fibula also are noted [8]. Abnormal dental eruptions, decay and premature loss of teeth are common, and patients have a deep voice, hearing loss and hirsutism. Cardiovascular defects, including patent ductus arteriosus, atrial and ventricular septal defects, mitral and aortic valve abnormalities leading to valvular insufficiency or stenosis have been reported in HCS [9],[10]. Respiratory infections can present in patients with HCS. Platybasia and basilar invagination are among the most serious complications of the disease and result in severe neurological problems, including hydrocephalus, central respiratory arrest and sudden death. Some patients present with renal cysts or polycystic kidneys, and serpentine fibula polycystic kidney syndrome seems to be the same disease as HCS.

Aetiology

Over 60 years after the original description, whole exome sequencing of individuals affected by HCS revealed the presence of mutations in exon 34, the terminal exon of NOTCH2. Either nonsense mutations or deletions leading to a shift in the open reading frame and the creation of a termination codon in exon 34 of NOTCH2 upstream the PEST domain are associated with HCS [11]-[14]. NOTCH2 transcript levels are equivalent and not lower than those observed in controls, indicating a reduced capacity to activate the process of nonsense-mediated mRNA decay. This is common in mutations affecting terminal exons of a gene. Since the PEST domain contains sequences necessary for the ubiquitinylation and degradation of NOTCH2 in the proteasome, the mutations lead to the accumulation of a stable protein and persistence of NOTCH2 signaling since all sequences required for the formation of the Notch transcriptional complex are upstream the PEST domain and are therefore preserved (Figure 1). NOTCH2 is located in Chromosome 1, 1p13 - p11.

Figure 1
figure1

Structure of NOTCH2 and mutations associated with Hajdu- Cheney syndrome. The extracellular domain (ECD) of Notch consists of multiple epidermal growth factor (EGF) repeats, upstream the transmembrane domain (TMD). The intracellular domain of NOTCH2 (NICD) consists of a transcriptional domain formed by the Rbpjκ association module (RAM) linked to ankyrin (ANK) repeats, and nuclear localization sequences. The C-terminus contains the proline (P)-, glutamic acid (E)-, serine (S)-, and threonine (T)-rich motifs (PEST) domain which is required for the ubiquitinylation and degradation of the NICD. Nonsense and deletion mutations in exon 34 associated with Hajdu-Cheney syndrome (HCS) and pointed by the arrow lead to the formation of a truncated protein consisting of all NOTCH2 sequences necessary for the formation of the transcriptional complex, but lacking the PEST domain needed for the ubiquitinylation and degradation of NOTCH2. As such, a stable and active NOTCH2 protein is synthesized.

Full size image

It is of interest that somatic NOTCH2 mutations causing loss of the PEST domain have been identified in B cell lymphoma, specifically in splenic marginal zone lymphoma [15]-[18]. These mutants exhibit enhanced transactivating activity in Notch reporter assays in vitro demonstrating that absence of the PEST domain leads to enhanced Notch activation [15],[16]

Despite the pronounced skeletal abnormalities reported in HCS, little is known regarding the mechanisms underlying the bone loss. Although the distal phalangeal osteolytic lesions suggest increased localized bone resorption, there is no information on the mechanisms responsible for the generalized osteoporosis. The focal osteolysis is accompanied by neovascularization, inflammation and fibrosis [19]-[21]. Tissue from iliac crest biopsies has been examined in a small number of cases of HCS and revealed decreased trabecular bone, normal or increased bone remodeling, and normal or decreased bone formation [21]-[24]. In two published cases, increased number of osteoclasts with normal or increased osteoblasts were found suggesting that increased bone resorption may be responsible for the bone phenotype [21],[25]. These observations are compatible with the known effects of Notch2 on the murine skeleton. In osteoclast precursors, Notch2 induces Nuclear factor of T-cells 1 transcription and osteoclastogenesis, and this effect could explain the increased bone remodeling [26],[27]. Whether the osteoblast/osteocyte are also responsible for changes in bone turnover has not been established.

Mechanisms responsible for the craniofacial developmental abnormalities probably relate to the effects of Notch on skeletal development, and the short stature may be secondary to the inhibitory effects of Notch on chondrogenesis. Less is known about potential mechanisms to explain the periodontal disease and tooth loss and those responsible for the polycystic kidney disease. Notch plays a role in cardiovascular development and angiogenesis, and this would explain the congenital heart defects.

Missense mutations in exon 34 of NOTCH2, upstream of sequences encoding for the PEST domain, also have been detected in patients affected by serpentine fibula-polycystic kidney syndrome and the mutations are similar to those associated with HCS [4],[28],[29].

Diagnosis

Patients with HCS have distinct radiologic findings, including acroosteolysis of distal phalanges of hands and feet. Plain radiographs of the skull reveal open sutures, intra sutural bones, abnormal flattening of the base of the skull, elongated sella turcica and absent frontal sinuses. Radiographs of the spine reveal bone loss and fractures. In addition, bone mineral density can be utilized to determine the presence of osteoporosis, although caution is required for its interpretation since diagnostic criteria established for postmenopausal osteoporosis may or may not apply. This is the case, for instance, with most forms of secondary osteoporosis, where a correlation between bone mineral density and fracture risk has not been established [30],[31].

Based on a limited number of cases reported so far, the common pathogenetic mechanism in HCS seems to involve nonsense or deletion mutations in exon 34 of NOTCH2, resulting in a protein product lacking the PEST domain. Based on this information, the diagnosis of HCS would be carried out by sequence analysis of exon 34 of NOTCH2. For this purpose, genomic DNA is isolated from peripheral leukocytes and exon 34 amplified by polymerase chain reaction (PCR) using specific primers followed by sequence analysis of the PCR product [32].

Differential diagnosis

HCS can present with a wide range of skeletal and non-skeletal manifestations so that the differential diagnosis may include a large array of clinical conditions. Acroosteolysis can be secondary to autoimmune disorders, such as scleroderma, systemic lupus erythematosus, Sjogren’s syndrome, rheumatoid arthritis and Raynaud’s disease; frostbite and injuries; neuropathies; diabetes mellitus; porphyria and psoriasis [19]. Osteoporosis, primary and secondary, should be considered in the differential diagnosis of HCS [33],[34]. Werner’s syndrome and progeria, osteogenesis imperfecta and other rare skeletal disorders, such as Ehlers-Danlos syndrome, cleidocranial dysplasia, idiopathic juvenile osteoporosis also form part of the differential diagnosis [35].

Genetic counseling and antenatal diagnosis

Most cases of HCS are sporadic, although in certain families autosomal dominant transmission is found [11]-[13].

There is limited information on genetic counseling and antenatal diagnosis regarding HCS. This is in part because the disease is rare, and because many cases of HCS are sporadic. In inherited cases, prenatal diagnosis could entail NOTCH2 gene sequence analysis, although as indicated under Diagnosis, the number of HCS cases associated with NOTCH2 mutations is limited and other gene mutations are possible. There is limited information about the penetrance of the disease, and it is conceivable that selected patients presenting with severe idiopathic osteoporosis are low penetrance cases of HCS.

Management, including treatment of skeletal manifestations

The management of HCS requires a multi-system approach related to the organs affected by the disease in a given patient. Although patients develop acroosteolysis and osteoporosis, the mechanism of the bone loss is not known, making decisions regarding therapeutic interventions difficult. The acroosteolysis seems related to an inflammatory process. There are no controlled trials on the management of the osteoporosis; only anecdotal cases treated with either bisphosphonates or teriparatide. Bisphosphonate therapy (alendronate and pamidronate) alone or in combination with anabolic therapy with teriparatide has been attempted for the treatment of the skeletal manifestations of patients with HCS, but there is no clear evidence that either therapy is beneficial [36],[37]. Teriparatide recently was shown to increase bone mineral density in a patient with HCS, but whether bisphosphonates or teriparatide offer fracture protection is not known [7]. Importantly, long-term activation of Notch signaling causes osteosarcoma in experimental mouse models, a potential concern when considering the use of teriparatide [38].

There is reasonable evidence indicating that activation of NOTCH2 signaling causes HCS, and NOTCH2 itself could be a future target for the treatment of the disease. Experimental modalities to control Notch signaling have been reported, including the use of antibodies to the Notch extracellular domain or its ligands, and the use of cell membrane permeable peptides that interfere with the formation of the Notch transcriptional complex [39],[40]. These approaches could form the basis for the development of future therapies for HCS. However, reduced Notch signaling can result in the formation of vascular tumors in experimental animals [41]. There have been no studies reported in humans exploring these therapeutic approaches to block NOTCH2 signaling [41].

Prognosis

HCS is a serious disease, but there is limited information about the overall prognosis of affected patients, and the prognosis is dependent on the organs affected and the complications of the disease. The natural evolution of HCS leads to the development of acroosteolysis and osteoporosis with fractures. As a consequence of the fractures, morbidity and mortality are increased [42]. The prognosis of patients with HCS is not favorable when there is evidence of neurological impairment. Basilar invagination is one of the most serious complications of HCS, and can occur in about 50% of the cases and result in neurological complications including central respiratory arrest [6]. Due to the limited number of cases, it is not possible to know whether lifespan is reduced, although it is reasonable to believe that patients with severe neurological complications may suffer from reduced lifespan.

Molecular basis

Bone remodeling consists in the coordinated resorption and formation of bone, a process that requires the integrated involvement of cells of the osteoclast and osteoblast lineage and of signals released by these cells [43]-[48]. Osteoclasts are multinucleated cells derived from the fusion of mononuclear precursors of the hematopoietic lineage. The formation of osteoclasts requires receptor activator of nuclear factor κ-B ligand (RANKL) and macrophage colony stimulating factor (M-CSF) [49]. Osteoblasts are cells of mesenchymal origin, and their differentiation is tightly regulated by specific signals [50]-[53]. As osteoblasts become differentiated, they encounter various terminal destinies, including becoming embedded in distinct lacunae in the bone matrix as osteocytes, cells that play a fundamental role in mechanotransduction [54].

Notch 1 to 4 are single-pass transmembrane receptors that play a critical role in cell fate decisions [55]-[60]. Notch has a complex structure, and its extracellular domain contains multiple epidermal growth factor-like tandem repeats upstream a negative regulatory region. Downstream the transmembrane domain, there is a Notch intracellular domain (NICD) consisting of an RBPJκ association module linked to ankyrin repeats, and together they form the Notch transcriptional domain. The C terminus contains the Proline (P), glutamic acid (E), serine (S) and threonine (T) rich (PEST) domain which is required for the ubiquitinylation and degradation of the NICD (Figure 1). There are five classic Notch ligands, which are Jagged1 and 2, and Delta Like1, 3 and 4 [61]. Notch-ligand interactions result in the proteolytic cleavage and release of the NICD, which translocates to the nucleus and interacts with Rbpjκ, and with Mastermind-like proteins to regulate transcription (Figure 2) [62]-[65]. This is termed the canonical signaling pathway, which leads to the transcription of Hairy and enhancer of split (Hes) 1, 5 and 7 and Hes-related with YRPW motif (Hey) 1, 2 and L [66]. The Notch non-canonical signaling pathway does not require Rbpjκ [61],[67].

Figure 2
figure2

Activation of Notch signaling. Notch receptors and Jagged/Delta ligands are expressed as single-pass transmembrane proteins. Receptor-ligand interactions lead to the cleavage of the Notch receptor and release of the Notch intracellular domain (NICD) to the cytoplasm. NICD translocates to the nucleus and forms a ternary complex with Rbpjκ and Mastermind-like, displacing transcriptional repressors and associating with transcriptional activators, and inducing expression of Notch target genes.

Full size image

Skeletal cells express Notch1, Notch2 and low levels of Notch3 transcripts [68]-[70]. Notch regulates cell renewal in multiple organs and cell systems, and it is involved in skeletal development and homeostasis, and in osteoblast and osteoclast differentiation [57],[61],[71],[72]. Transgenic overexpression of Notch1 NICD in cells of the osteoblastic lineage impairs osteoblast differentiation/function and causes osteopenia [72]. Notch signaling also suppresses chondrogenesis [57],[73]-[80]. The effects of Notch in cells of the osteoblastic lineage are cell-context dependent and determined by the degree of differentiation of the cells targeted by Notch. When Notch is activated in undifferentiated cells of the osteoblastic lineage, it suppresses their progression to maturity and inhibits osteoblast function leading to the suppression of bone formation and as a consequence to bone loss [81]. In contrast, activation of Notch in mature osteoblasts and in osteocytes increases trabecular bone mass due to suppressed osteoclast formation and decreased bone resorption [81],[82]. Accordingly, developmental or post-natal inactivation of Notch1 and Notch2 in osteoblast progenitors enhances cancellous bone volume by increasing osteoblast number and activity [57],[83].

Most of the studies reported on the function of Notch in the skeleton have examined Notch1, so that less is known regarding the function of Notch2, 3 and 4. Notch1 and Notch 2 retain structural similarity, but these receptors have distinct activities, and global null mutations of either receptor result in embryonic lethality, indicating that they do not have redundant functions [84]-[87]. In contrast to the inhibitory effects of Notch1 on osteoclastogenesis, Notch2 enhances osteoclastogenesis [27],[88].

Unresolved questions

Current evidence indicates an association between mutations in Exon 34 of NOTCH2 and HCS. However, the exact mechanisms by which NOTCH2 causes the manifestations of HCS are not known. Limited bone histological analysis has resulted in inconclusive results. It is not established whether the bone loss is the result of increased bone resorption, decreased bone formation or both. As a consequence, it is difficult to make optimal therapeutic decisions, and it is not known whether anti-resorptive and anabolic therapy will reduce the incidence of fractures in patients affected by the disease. Specific inactivation of NOTCH2 signaling by use of anti-NOTCH2 antibodies or soluble peptides that interfere with the formation of the transcriptional complex may offer novel alternative treatments. However, appropriate clinical trials are necessary to establish their effectiveness and potential adverse event profile. The pathogenesis of the acroosteolysis may be inflammatory leading to localized bone resorption but necessary studies to establish mechanisms involved are lacking and need to be conducted.

Mouse models of HCS, where mutations are introduced in Exon 34 of Notch2 upstream the PEST domain should serve to study the disease, explore mechanisms involved and ways to reverse phenotypic manifestations. These should form the basis for a better understanding of the disease.

Conclusions

Genetic mutations causing either gain- or loss-of-function of various components of the Notch signaling pathway are associated with diverse skeletal disorders, confirming that Notch is critical for skeletal development and homeostasis. Findings in human diseases are consistent with results of numerous pre-clinical studies. Although HCS affects a limited number of individuals, discovering a cluster of mutations in a single domain of NOTCH2 in patients with HCS has advanced our knowledge regarding potential mechanisms leading to bone loss.

In conclusion, Notch signaling is required for skeletal development and bone homeostasis and diseases associated with dysregulation of Notch signaling are uncommon, but present with severe clinical manifestations.

Abbreviations

ANK:

Ankyrin

ECD:

Extracellular domain

EGF:

Epidermal growth factor

HCS:

Hajdu-Cheney syndrome

Hes :

Hairy enhancer of split

Hey :

Hes-related with YRPW-motif

M-CSF:

Macrophage colony stimulating factor

NICD:

Notch intracellular domain

PEST:

Proline (P), glutamic acid (E), serine (S) and threonine (T) rich

PCR:

Polymerase chain reaction

RAM:

Rbpjκ association module

RANKL:

Receptor activator of nuclear factor κ-B ligand

TMD:

Transmembrane domain

References

  1. 1.

    Cheney WD: Acro-Osteolysis. Am J Roentgenol Radium Ther Nucl Med. 1965, 94: 595-607.

    CAS  PubMed  Google Scholar 

  2. 2.

    Hajdu N, Kauntze R: Cranio-skeletal dysplasia. Br J Radiol. 1948, 21: 42-48. 10.1259/0007-1285-21-241-42.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Currarino G: Hajdu-Cheney syndrome associated with serpentine fibulae and polycystic kidney disease. Pediatr Radiol. 2009, 39: 47-52. 10.1007/s00247-008-0992-9.

    Article  PubMed  Google Scholar 

  4. 4.

    Gray MJ, Kim CA, Bertola DR, Arantes PR, Stewart H, Simpson MA, Irving MD, Robertson SP: Serpentine fibula polycystic kidney syndrome is part of the phenotypic spectrum of Hajdu-Cheney syndrome. Eur J Hum Genet. 2012, 20: 122-124. 10.1038/ejhg.2011.125.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Silverman FN, Dorst JP, Hajdu N: Acroosteolysis (Hajdu-Cheney syndrome). Birth Defects Orig Artic Ser. 1974, 10: 106-123.

    CAS  PubMed  Google Scholar 

  6. 6.

    Brennan AM, Pauli RM: Hajdu–Cheney syndrome: evolution of phenotype and clinical problems. Am J Med Genet. 2001, 100: 292-310. 10.1002/1096-8628(20010515)100:4<292::AID-AJMG1308>3.0.CO;2-4.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Descartes M, Rojnueangnit K, Cole L, Sutton A, Morgan SL, Patry L, Samuels ME: Hajdu-Cheney syndrome: phenotypical progression with de-novo NOTCH2 mutation. Clin Dysmorphol. 2014, 23: 88-94. 10.1097/MCD.0000000000000034.

    Article  PubMed  Google Scholar 

  8. 8.

    Stathopoulos IP, Trovas G, Lampropoulou-Adamidou K, Koromila T, Kollia P, Papaioannou NA, Lyritis G: Severe osteoporosis and mutation in NOTCH2 gene in a woman with Hajdu-Cheney syndrome. Bone. 2013, 52: 366-371. 10.1016/j.bone.2012.10.027.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Kaler SG, Geggel RL, Sadeghi-Nejad A: Hajdu-Cheney syndrome associated with severe cardiac valvular and conduction disease . Dysmorph Clin Genet. 1990, 4: 43-47.

    Google Scholar 

  10. 10.

    Sargin G, Cildag S, Senturk T: Hajdu-Cheney syndrome with ventricular septal defect. Kaohsiung J Med Sci. 2013, 29: 343-344. 10.1016/j.kjms.2012.10.009.

    Article  PubMed  Google Scholar 

  11. 11.

    Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, Martin-Coignard D, Thauvin-Robinet C, Le MM, Mandel JL, David A, Faivre L, Cormier-Daire V, Redon R, Le CC: Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet. 2011, 43: 306-308. 10.1038/ng.778.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Majewski J, Schwartzentruber JA, Caqueret A, Patry L, Marcadier J, Fryns JP, Boycott KM, Ste-Marie LG, McKiernan FE, Marik I, Van EH, Michaud JL, Samuels ME: Mutations in NOTCH2 in families with Hajdu-Cheney syndrome. Hum Mutat. 2011, 32: 1114-1117. 10.1002/humu.21546.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Simpson MA, Irving MD, Asilmaz E, Gray MJ, Dafou D, Elmslie FV, Mansour S, Holder SE, Brain CE, Burton BK, Kim KH, Pauli RM, Aftimos S, Stewart H, Kim CA, Holder-Espinasse M, Robertson SP, Drake WM, Trembath RC: Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet. 2011, 43: 303-305. 10.1038/ng.779.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Zhao W, Petit E, Gafni RI, Collins MT, Robey PG, Seton M, Miller KK, Mannstadt M: Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome. Osteoporos Int. 2013, 24: 2275-2281. 10.1007/s00198-013-2298-5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Zhang X, Shi Y, Weng Y, Lai Q, Luo T, Zhao J, Ren G, Li W, Pan H, Ke Y, Zhang W, He Q, Wang Q, Zhou R: The Truncate Mutation of Notch2 Enhances Cell Proliferation through Activating the NF-kappaB Signal Pathway in the Diffuse Large B-Cell Lymphomas. PLoS One. 2014, 9: e108747-10.1371/journal.pone.0108747.

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, Izutsu K, Sakata-Yanagimoto M, Hangaishi A, Yagita H, Fukayama M, Seto M, Kurokawa M, Ogawa S, Chiba S: Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009, 100: 920-926. 10.1111/j.1349-7006.2009.01130.x.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS: Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012, 209: 1553-1565. 10.1084/jem.20120910.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbo F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, et al: The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012, 209: 1537-1551. 10.1084/jem.20120904.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Elias AN, Pinals RS, Anderson HC, Gould LV, Streeten DH: Hereditary osteodysplasia with acro-osteolysis. (The Hajdu-Cheney syndrome). Am J Med. 1978, 65: 627-636. 10.1016/0002-9343(78)90851-3.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Nunziata V, Di GG, Ballanti P, Bonucci E: High turnover osteoporosis in acro-osteolysis (Hajdu-Cheney syndrome). J Endocrinol Invest. 1990, 13: 251-255. 10.1007/BF03349553.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Udell J, Schumacher HR, Kaplan F, Fallon MD: Idiopathic familial acroosteolysis: histomorphometric study of bone and literature review of the Hajdu-Cheney syndrome. Arthritis Rheum. 1986, 29: 1032-1038. 10.1002/art.1780290815.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Avela K, Valanne L, Helenius I, Makitie O: Hajdu-Cheney syndrome with severe dural ectasia. Am J Med Genet A. 2011, 155A: 595-598. 10.1002/ajmg.a.33510.

    Article  PubMed  Google Scholar 

  23. 23.

    Blumenauer BT, Cranney AB, Goldstein R: Acro-osteolysis and osteoporosis as manifestations of the Hajdu-Cheney syndrome. Clin Exp Rheumatol. 2002, 20: 574-575.

    CAS  PubMed  Google Scholar 

  24. 24.

    Brown DM, Bradford DS, Gorlin RJ, Desnick RJ, Langer LO, Jowsey J, Sauk JJ: The acro-osteolysis syndrome: Morphologic and biochemical studies. J Pediatr. 1976, 88: 573-580. 10.1016/S0022-3476(76)80009-1.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Leidig-Bruckner G, Pfeilschifter J, Penning N, Limberg B, Priemel M, Delling G, Ziegler R: Severe osteoporosis in familial Hajdu-Cheney syndrome: progression of acro-osteolysis and osteoporosis during long-term follow-up. J Bone Miner Res. 1999, 14: 2036-2041. 10.1359/jbmr.1999.14.12.2036.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Ikeda F, Nishimura R, Matsubara T, Hata K, Reddy SV, Yoneda T: Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. J Immunol. 2006, 177: 2384-2390. 10.4049/jimmunol.177.4.2384.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Fukushima H, Nakao A, Okamoto F, Shin M, Kajiya H, Sakano S, Bigas A, Jimi E, Okabe K: The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol. 2008, 28: 6402-6412. 10.1128/MCB.00299-08.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Isidor B, Le MM, Exner GU, Pichon O, Thierry G, Guiochon-Mantel A, David A, Cormier-Daire V, Le CC: Serpentine fibula-polycystic kidney syndrome caused by truncating mutations in NOTCH2. Hum Mutat. 2011, 32: 1239-1242. 10.1002/humu.21563.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Majewski F, Enders H, Ranke MB, Voit T: Serpentine fibula–polycystic kidney syndrome and Melnick-Needles syndrome are different disorders. Eur J Pediatr. 1993, 152: 916-921. 10.1007/BF01957530.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Canalis E, Mazziotti G, Giustina A, Bilezikian JP: Glucorticoid-Induced Osteoporosis: Pathophysiology and Therapy. Osteoporos Int. 2007, 18: 1319-1328. 10.1007/s00198-007-0394-0.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Mazziotti G, Canalis E, Giustina A: Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010, 123: 877-884. 10.1016/j.amjmed.2010.02.028.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Narumi Y, Min BJ, Shimizu K, Kazukawa I, Sameshima K, Nakamura K, Kosho T, Rhee Y, Chung YS, Kim OH, Fukushima Y, Park WY, Nishimura G: Clinical consequences in truncating mutations in exon 34 of NOTCH2: report of six patients with Hajdu-Cheney syndrome and a patient with serpentine fibula polycystic kidney syndrome . Am J Med Genet A. 2013, 161a: 518-526. 10.1002/ajmg.a.35772.

    Article  PubMed  Google Scholar 

  33. 33.

    Franchimont N, Canalis E: Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev. 2003, 2: 224-228. 10.1016/S1568-9972(03)00056-9.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Miller PD: Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am. 2012, 41: 613-628. 10.1016/j.ecl.2012.05.005.

    Article  PubMed  Google Scholar 

  35. 35.

    Mannstadt M, Lin AE, Le LP: Case records of the Massachusetts General Hospital. Case 24–2014. A 27-year-old man with severe osteoporosis and multiple bone fractures. N Engl J Med. 2014, 371: 465-472. 10.1056/NEJMcpc1404139.

    Article  PubMed  Google Scholar 

  36. 36.

    Galli-Tsinopoulou A, Kyrgios I, Giza S, Giannopoulou EM, Maggana I, Laliotis N: Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. Minerva Endocrinol. 2012, 37: 283-289.

    CAS  PubMed  Google Scholar 

  37. 37.

    McKiernan FE: Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome: 2-year follow-up. Osteoporos Int. 2008, 19: 379-380. 10.1007/s00198-007-0461-6.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Tao J, Jiang MM, Jiang L, Salvo JS, Zeng HC, Dawson B, Bertin TK, Rao PH, Chen R, Donehower LA, Gannon F, Lee BH: Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014, 26: 390-401. 10.1016/j.ccr.2014.07.023.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Moellering RE, Cornejo M, Davis TN, Del BC, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE: Direct inhibition of the NOTCH transcription factor complex. Nature. 2009, 462: 182-188. 10.1038/nature08543.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Ryeom SW: The cautionary tale of side effects of chronic Notch1 inhibition. J Clin Invest. 2011, 121: 508-509. 10.1172/JCI45976.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, Piwnica-Worms DR, Kopan R: Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest. 2011, 121: 800-808. 10.1172/JCI43114.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR: Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999, 159: 1215-1220. 10.1001/archinte.159.11.1215.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Canalis E, Giustina A, Bilezikian JP: Mechanisms of Anabolic Therapies for Osteoporosis. N Engl J Med. 2007, 357: 905-916. 10.1056/NEJMra067395.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Canalis E: The fate of circulating osteoblasts. N Engl J Med. 2005, 352: 2014-2016. 10.1056/NEJMe058080.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Parfitt AM: The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res. 2001, 16: 1583-1585. 10.1359/jbmr.2001.16.9.1583.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Seeman E, Delmas PD: Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med. 2006, 354: 2250-2261. 10.1056/NEJMra053077.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Sims NA, Martin TJ: Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKEy reports. 2014, 3: 481-

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Martin TJ: Coupling factors: how many candidates can there be?. J Bone Miner Res. 2014, 29: 1519-1521. 10.1002/jbmr.2276.

    Article  PubMed  Google Scholar 

  49. 49.

    Teitelbaum SL: Osteoclasts: what do they do and how do they do it?. Am J Pathol. 2007, 170: 427-435. 10.2353/ajpath.2007.060834.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Canalis E: Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013, 9: 575-583. 10.1038/nrendo.2013.154.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Canalis E, Economides AN, Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev. 2003, 24: 218-235. 10.1210/er.2002-0023.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Gazzerro E, Canalis E: Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord. 2006, 7: 51-65. 10.1007/s11154-006-9000-6.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ: Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012, 492: 1-18. 10.1016/j.gene.2011.10.044.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Dallas SL, Prideaux M, Bonewald LF: The osteocyte: an endocrine cell … and more. Endocr Rev. 2013, 34: 658-690. 10.1210/er.2012-1026.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Zanotti S, Canalis E: Notch regulation of bone development and remodeling and related skeletal disorders. Calcif Tissue Int. 2012, 90: 69-75. 10.1007/s00223-011-9541-x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Zanotti S, Canalis E: Notch signaling in skeletal health and disease. Eur J Endocrinol. 2013, 168: R95-R103. 10.1530/EJE-13-0115.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F: Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med. 2008, 14: 306-314. 10.1038/nm1716.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Fortini ME: Notch signaling: the core pathway and its posttranslational regulation. Dev Cell. 2009, 16: 633-647. 10.1016/j.devcel.2009.03.010.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Mumm JS, Kopan R: Notch signaling: from the outside in. Dev Biol. 2000, 228: 151-165. 10.1006/dbio.2000.9960.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Sahlgren C, Lendahl U: Notch signaling and its integration with other signaling mechanisms. Regen Med. 2006, 1: 195-205. 10.2217/17460751.1.2.195.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Zanotti S, Canalis E: Notch and the Skeleton. Mol Cell Biol. 2010, 30: 886-896. 10.1128/MCB.01285-09.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Kovall RA: More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene. 2008, 27: 5099-5109. 10.1038/onc.2008.223.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Nam Y, Sliz P, Song L, Aster JC, Blacklow SC: Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell. 2006, 124: 973-983. 10.1016/j.cell.2005.12.037.

    CAS  Article  PubMed  Google Scholar 

  64. 64.

    Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998, 393: 382-386. 10.1038/30756.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Wilson JJ, Kovall RA: Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell. 2006, 124: 985-996. 10.1016/j.cell.2006.01.035.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Iso T, Kedes L, Hamamori Y: HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003, 194: 237-255. 10.1002/jcp.10208.

    CAS  Article  PubMed  Google Scholar 

  67. 67.

    Andersen P, Uosaki H, Shenje LT, Kwon C: Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol. 2012, 22: 257-265. 10.1016/j.tcb.2012.02.003.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL: NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem. 2008, 283: 6509-6518. 10.1074/jbc.M707000200.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Dallas DJ, Genever PG, Patton AJ, Millichip MI, McKie N, Skerry TM: Localization of ADAM10 and Notch receptors in bone. Bone. 1999, 25: 9-15. 10.1016/S8756-3282(99)00099-X.

    CAS  Article  PubMed  Google Scholar 

  70. 70.

    Pereira RM, Delany AM, Durant D, Canalis E: Cortisol regulates the expression of Notch in osteoblasts. J Cell Biochem. 2002, 85: 252-258. 10.1002/jcb.10125.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    Engin F, Yao Z, Yang T, Zhou G, Bertin T, Jiang MM, Chen Y, Wang L, Zheng H, Sutton RE, Boyce BF, Lee B: Dimorphic effects of Notch signaling in bone homeostasis. Nat Med. 2008, 14: 299-305. 10.1038/nm1712.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E: Notch Inhibits Osteoblast Differentiation And Causes Osteopenia. Endocrinology. 2008, 149: 3890-3899. 10.1210/en.2008-0140.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Dong Y, Jesse AM, Kohn A, Gunnell LM, Honjo T, Zuscik MJ, O'Keefe RJ, Hilton MJ: RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development. 2010, 137: 1461-1471. 10.1242/dev.042911.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Francis JC, Radtke F, Logan MP: Notch1 signals through Jagged2 to regulate apoptosis in the apical ectodermal ridge of the developing limb bud. Dev Dyn. 2005, 234: 1006-1015. 10.1002/dvdy.20590.

    CAS  Article  PubMed  Google Scholar 

  75. 75.

    Kageyama R, Masamizu Y, Niwa Y: Oscillator mechanism of Notch pathway in the segmentation clock. Dev Dyn. 2007, 236: 1403-1409. 10.1002/dvdy.21114.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Zanotti S, Smerdel-Ramoya A, Canalis E: Hairy and enhancer of split (HES)1 is a determinant of bone mass. J Biol Chem. 2011, 286: 2648-2657. 10.1074/jbc.M110.183038.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Chen S, Tao J, Bae Y, Jiang MM, Bertin T, Chen Y, Yang T, Lee B: Notch gain of function inhibits chondrocyte differentiation via Rbpj-dependent suppression of Sox9. J Bone Miner Res. 2013, 28: 649-659. 10.1002/jbmr.1770.

    Article  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Kohn A, Dong Y, Mirando AJ, Jesse AM, Honjo T, Zuscik MJ, O'Keefe RJ, Hilton MJ: Cartilage-specific RBPjkappa-dependent and -independent Notch signals regulate cartilage and bone development. Development. 2012, 139: 1198-1212. 10.1242/dev.070649.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Mead TJ, Yutzey KE: Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A. 2009, 106: 14420-14425. 10.1073/pnas.0902306106.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  80. 80.

    Zanotti S, Canalis E: Notch suppresses nuclear factor of activated T cells (Nfat) transactivation and Nfatc1 expression in chondrocytes. Endocrinology. 2013, 154: 762-772. 10.1210/en.2012-1925.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Canalis E, Parker K, Feng JQ, Zanotti S: Osteoblast Lineage-specific Effects of Notch Activation in the Skeleton. Endocrinology. 2013, 154: 623-634. 10.1210/en.2012-1732.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Canalis E, Adams DJ, Boskey A, Parker K, Kranz L, Zanotti S: Notch Signaling in Osteocytes Differentially Regulates Cancellous and Cortical Bone Remodeling. J Biol Chem. 2013, 288: 25614-25625. 10.1074/jbc.M113.470492.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  83. 83.

    Zanotti S, Canalis E: Notch1 and Notch2 expression in osteoblast precursors regulates femoral microarchitecture. Bone. 2014, 62: 22-28. 10.1016/j.bone.2014.01.023.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Bigas A, Martin DI, Milner LA: Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines. Mol Cell Biol. 1998, 18: 2324-2333.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  85. 85.

    Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T: Notch1 is essential for postimplantation development in mice. Genes Dev. 1994, 8: 707-719. 10.1101/gad.8.6.707.

    CAS  Article  PubMed  Google Scholar 

  86. 86.

    Conlon RA, Reaume AG, Rossant J: Notch1 is required for the coordinate segmentation of somites. Development. 1995, 121: 1533-1545.

    CAS  PubMed  Google Scholar 

  87. 87.

    Weinmaster G, Roberts VJ, Lemke G: Notch2: a second mammalian Notch gene. Development. 1992, 116: 931-941.

    CAS  PubMed  Google Scholar 

  88. 88.

    Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H: Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther. 2012, 14: R45-10.1186/ar3758.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by grant DK045227 (EC) from the National Institute of Diabetes, Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.

Author information

Affiliations

  1. Departments of Orthopaedic Surgery and Medicine, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030, USA

    Ernesto Canalis & Stefano Zanotti

Authors
  1. Ernesto Canalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Zanotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernesto Canalis.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

EC and SZ participated in the conception and writing of the manuscript. Both authors have read and approve the manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Canalis, E., Zanotti, S. Hajdu-Cheney syndrome: a review. Orphanet J Rare Dis 9, 200 (2014). https://doi.org/10.1186/s13023-014-0200-y

Download citation

Keywords

  • Notch
  • Skeleton
  • Bone remodeling
  • Hajdu-Cheney syndrome
  • Fractures
  • Polycystic kidneys
  • B cell lymphoma

Orphanet Journal of Rare Diseases

ISSN: 1750-1172